JPRN-C000000251已完成3 期
A Phase III Study of Docetaxel and S-1 versus S-1 in the Treatment of Advanced Gastric Cancer - START (S-1 and Taxotere therapy for Advanced GC Randomized phase III Trial)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 628
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Active double cancer (except early stage colorectal cancer) 2.Gastrointestinal bleeding. 3.Excessive amounts of ascites require drainage. 4.Known brain metastases. 5.Symptomatic peripheral neuropathy ≥ grade 2. by NCI-CTCAE ver.3.0 6.Pulmonary fibrosis, Interstitial pneumonitis. 7.History of hypersensitivity to fluoropyrimidines, docetaxel, or medications formulated with polysorbate 80. 8.Any previous chemotherapy or radiotherapy for AGC. 9.Pregnancy or lactation women, or women with suspected pregnancy or men with willing to get pregnant. 10.Treatment with any investigational product during the last 4 weeks prior to study entry. 11.Definite contraindications for the use of corticosteroids. 12.Any subject judged by the investigator to be unfit for any reason to participate in the study
研究者
相似试验
已完成
不适用
A Phase III Study of Docetaxel plus S-1 versus S-1 Alone in the Treatment of Curatively Resected Stage III Gastric CancerGastric CancerJPRN-UMIN000010337Japan Clinical Cancer Reseach Organization (JACCRO)1,100
已完成
1 期
Phase I/II Study of Docetaxel and S-1 Combination Therapy for Advanced Non-small Cell Lung CancerJPRN-C000000281The Tokyo Cooperative Oncology Group60
已完成
2 期
Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric CancerMetastatic gastric cancer (Advanced or recurrent gastric cancer)JPRN-C000000103Hiroshima Cancer Therapy Development Organization (HiCTDO)50
暂停
2 期
A Phase II trial of S-1 and Docetaxel followed by FEC as neoadjuvant chemotherapy for primary breast cancerBreast CancerJPRN-UMIN000005100Keio University School of Medicine40
已完成
3 期
Phase3 study of docetaxel/TS-1 versus docetaxel in patients with previously treated non-small cell lung canceron-small cell lung cancer patients with postoperative recurrence or stage3-4 with chemotherapy treatment historyJPRN-UMIN000011391Kanto respiratory disease study group260